Drugs / IO-108
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05508100 | Sep 2022 → Apr 2024 | neoplasm | Immune-Onc Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT05054348 | Sep 2021 → Apr 2024 | cancer | Immune-Onc Therapeutics | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04524871 | Nov 2020 → Jul 2027 expected | liver cancer | Hoffmann-La Roche | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IO-108 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05054348 ↗ |
| Route | Intravenous | “IO-108 will be administered at a dose 1800 mg by IV infusion on Day 1 of each 21 day cycle.” NCT04524871 ↗ |